Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2001-03-14 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2001-03-14 English
8-K
Regulatory Filings
2000-11-27 English
THIRD QUARTER FORM 10-QSB
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB, which is a quarterly report filed pursuant to the Securities Exchange Act of 1934. It contains unaudited interim financial statements, management's discussion and analysis of financial condition and results of operations, notes to consolidated financial statements, and other detailed financial and operational information for the quarterly period ended September 30, 2000. The presence of detailed financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document is not an announcement or a certification but the actual report itself, and it is not a full annual report (10-K). Therefore, the correct classification is Interim / Quarterly Report (IR).
2000-11-14 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the U.S. SEC, dated November 10, 2000. It announces the election of a new director, Gary Powers, to the company's board. The content focuses on management changes and biographical details of directors and officers. There are no financial statements or detailed financial performance data included. The primary subject is the change in the board of directors, which fits the category of Board/Management Information (MANG). The document length is 7455 characters, sufficient to contain substantive information about management changes rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2000-11-13 English
CURRENT REPORT
Regulatory Filings
2000-10-12 English
QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB, which is a quarterly report filed pursuant to the Securities Exchange Act of 1934. It covers the quarterly period ended June 30, 2000, and includes consolidated financial statements, management's discussion and analysis, and detailed financial data for the quarter. The presence of unaudited interim financial statements and the quarterly period reference clearly indicate this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2000-08-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.